
Caribou Biosciences (CRBU) Stock Forecast & Price Target
Caribou Biosciences (CRBU) Analyst Ratings
Bulls say
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company that is well-positioned for success, with two promising CAR-T cell therapy candidates in its pipeline for the treatment of hematologic malignancies. The company has received multiple FDA designations, including RMAT, Fast Track, and Orphan Drug, which demonstrate the potential for expedited approval and commercialization. Initial data from its ongoing Phase 1 CaMMouflage trial shows strong efficacy results, including a 92% ORR and 91% MRD-negativity rate, indicating potential superiority over other BCMA or GPRC5D-targeted agents in the market. Analysts have reiterated a Buy rating and price target of $9 per share.
Bears say
Caribou Biosciences is reporting a narrower than expected net loss of $0.26 per share in 1Q26, with R&D and SG&A expenses coming in lower than projected. Despite still projecting a net loss for the full year, the company's cash position of $118.6M provides a runway into 2H27. With a lowered discount rate and a raised price target of $11 per share, the company reiterates a Buy rating.
This aggregate rating is based on analysts' research of Caribou Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Caribou Biosciences (CRBU) Analyst Forecast & Price Prediction
Start investing in Caribou Biosciences (CRBU)
Order type
Buy in
Order amount
Est. shares
0 shares